# A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

> **NCT06605222** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 201 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SHR-7787 injection

## Key facts

- **NCT ID:** NCT06605222
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-04
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-11-30
- **Target enrollment:** 201 (ESTIMATED)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06605222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06605222, "A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06605222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*